Scolaris Content Display Scolaris Content Display

Cochrane Database of Systematic Reviews

Anti‐IL‐12/23p40 antibodies for maintenance of remission in Crohn's disease

Esta versión no es la más reciente

ver la versión actual 12 diciembre 2019

Información

DOI:
https://doi.org/10.1002/14651858.CD012804Copiar DOI
Base de datos:
  1. Cochrane Database of Systematic Reviews
Versión publicada:
  1. 26 septiembre 2017see what's new
Tipo:
  1. Intervention
Etapa:
  1. Protocol
Grupo Editorial Cochrane:

  1. Grupo Cochrane de Salud digestiva

Copyright:
  1. Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Cifras del artículo

Altmetric:

Citado por:

Citado 0 veces por enlace Crossref Cited-by

Contraer

Autores

  • Sarah C Davies

    Schulich School of Medicine & Dentistry, University of Western Ontario, London, Canada

  • Tran M Nguyen

    Cochrane IBD Group, Robarts Clinical Trials, London, Canada

  • Claire E Parker

    Robarts Clinical Trials, London, Canada

  • Reena Khanna

    Robarts Clinical Trials, London, Canada

    Department of Medicine, University of Western Ontario, London, Canada

  • Vipul Jairath

    Robarts Clinical Trials, London, Canada

    Department of Medicine, University of Western Ontario, London, Canada

    Department of Epidemiology and Biostatistics, University of Western Ontario, London, Canada

  • John K MacDonald

    Correspondencia a: Cochrane IBD Group, Robarts Clinical Trials, London, Canada

    [email protected]

    [email protected]

    Department of Medicine, University of Western Ontario, London, Canada

Declarations of interest

Sarah C Davies: None known

Tran M Nguyen: None known

Claire E Parker: None known

Reena Khanna has received consulting fees from AbbVie, Janssen, Pfizer, Shire, and Takeda. All of these activities are outside the submitted work.

Vipul Jairath: has received scientific advisory board fees from Abbvie, Sandoz, Ferring and Janssen; speaker's fees from Takeda and Ferring; and travel support for conference attendance from Vifor pharmaceuticals. All of these activities are outside the submitted work.

John K MacDonald: None known

Acknowledgements

Partial funding for the Cochrane IBD Group (April 1, 2016 ‐ March 31, 2018) has been provided by Crohn's and Colitis Canada (CCC).

Version history

Published

Title

Stage

Authors

Version

2019 Dec 12

Anti‐IL‐12/23p40 antibodies for maintenance of remission in Crohn's disease

Review

Sarah C Davies, Tran M Nguyen, Claire E Parker, John K MacDonald, Vipul Jairath, Reena Khanna

https://doi.org/10.1002/14651858.CD012804.pub2

2017 Sep 26

Anti‐IL‐12/23p40 antibodies for maintenance of remission in Crohn's disease

Protocol

Sarah C Davies, Tran M Nguyen, Claire E Parker, Reena Khanna, Vipul Jairath, John K MacDonald

https://doi.org/10.1002/14651858.CD012804

PICO

Population
Intervention
Comparison
Outcome

El uso y la enseñanza del modelo PICO están muy extendidos en el ámbito de la atención sanitaria basada en la evidencia para formular preguntas y estrategias de búsqueda y para caracterizar estudios o metanálisis clínicos. PICO son las siglas en inglés de cuatro posibles componentes de una pregunta de investigación: paciente, población o problema; intervención; comparación; desenlace (outcome).

Para saber más sobre el uso del modelo PICO, puede consultar el Manual Cochrane.